Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07720687

Template-Guided Burr-Hole Drainage With Middle Meningeal Artery Coagulation for Chronic Subdural Hematoma

Chronic subdural hematoma is a collection of blood and fluid on the surface of the brain that is common in older adults. Burr-hole drainage is a standard surgical treatment, but the hematoma may come back in some patients and require another procedure.This study will test whether using a patient-specific 3D-printed template to guide burr-hole placement, combined with coagulation of the middle meningeal artery during surgery, can reduce the risk of hematoma recurrence compared with standard burr-hole drainage.Participants with symptomatic chronic subdural hematoma who need surgery will be randomly assigned to one of two groups. One group will receive standard burr-hole drainage. The other group will receive 3D-printed template-guided burr-hole drainage with attempted intraoperative frontal branch of the middle meningeal artery coagulation when it can be safely performed.The main outcome is whether the hematoma comes back and requires another invasive treatment within 3 months after surgery. The study will also assess brain imaging results, neurological recovery, complications, hospital stay, and the feasibility and safety of the 3D-printed template and artery coagulation procedure.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Chronic subdural hematoma is a common neurosurgical disease, especially in older adults. Burr-hole drainage with closed-system drainage is widely used as standard surgical treatment. However, recurrence after surgery remains an important clinical problem and may require repeat invasive treatment.

The middle meningeal artery is believed to contribute to the blood supply of the outer membrane of chronic subdural hematoma. Interruption of middle meningeal artery flow may reduce repeated microbleeding and fluid exudation from the hematoma membrane. Endovascular middle meningeal artery embolization has shown promising results, but it requires angiographic equipment, interventional expertise, embolic materials, and additional cost.

This study evaluates a surgical strategy that combines patient-specific 3D-printed template guidance with burr-hole drainage and intraoperative middle meningeal artery coagulation. Preoperative thin-slice computed tomography images will be used to plan the burr-hole location and design a 3D-printed template. The template is intended to help surgeons locate a burr-hole site related to the expected course of the middle meningeal artery(frontal branch) while still allowing effective hematoma drainage.

Participants with symptomatic chronic subdural hematoma requiring burr-hole drainage will be randomly assigned to receive either standard burr-hole drainage or 3D-printed template-guided burr-hole drainage with attempted intraoperative middle meningeal artery coagulation when safely feasible.

The study will test whether this approach can reduce recurrence requiring repeat invasive treatment within 3 months after surgery. It will also assess clinical recovery, radiological changes, complications, resource use, and the feasibility and safety of template-guided localization and intraoperative artery coagulation.Patient safety will take priority over completion of the coagulation step. If the middle meningeal artery or a related branch cannot be clearly identified or safely coagulated during surgery, coagulation will not be performed, and standard hematoma drainage will be completed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with chronic subdural hematoma based on clinical symptoms and cranial CT or MRI.
  • Patients scheduled to undergo burr-hole drainage surgery.
  • Age 18 years or older.
  • Written informed consent obtained from the patient or legal representative. Exclusion Criteria
  • Acute subdural hematoma or other intracranial lesions requiring different surgical management.
  • Previous surgery for the same episode of chronic subdural hematoma.
  • Severe coagulation disorder or other contraindications to surgery.
  • Severe systemic disease making the patient unsuitable for participation.
  • Refusal or inability to provide informed consent.

Treatment and study plan

Standard Burr-Hole Drainage Group

Procedure

Standard burr-hole drainage performed according to routine clinical practice for chronic subdural hematoma.

3D-Printed Template-Guided Burr-Hole Drainage With Attempted MMA Coagulation Group

Procedure

Burr-hole drainage performed using a patient-specific 3D-printed template for surgical guidance, combined with attempted intraoperative coagulation of the middle meningeal artery.

Primary outcomes

  1. Recurrence of Chronic Subdural Hematoma Requiring Invasive Re-intervention within 3 Months after Surgery

    Time frame: Within 3 months after surgery

    Recurrence is defined as radiologically confirmed recurrent chronic subdural hematoma requiring repeat surgical intervention within 3 months after the initial surgery (e.g., repeat burr-hole drainage, craniotomy, endoscopic treatment, and/or MMA embolization).

Secondary outcomes

  1. Incidence of cSDH Recurrence (Hematoma Progression)

    Time frame: Within 3 months after surgery

    Incidence of cSDH Recurrence (Hematoma Progression): Hematoma progression will be defined as radiological increase in ipsilateral and/or bilateral subdural hematoma on follow-up imaging compared with the predefined postoperative baseline. Hematoma progression (Yes/No) will be considered present if any of the following criteria are met: (1) increase in maximal subdural hematoma thickness by ≥ 5 mm; (2) increase in midline shift by ≥ 3 mm; or (3) increase in hematoma cavity volume by ≥ 25%. The incidence will be reported as a percentage.

  2. Functional Outcome Measured by the Modified Rankin Scale (mRS)

    Time frame: Within 3 months after surgery

    Functional Outcome Measured by the Modified Rankin Scale (mRS): Functional status will be measured using the Modified Rankin Scale (mRS), a 7-point ordinal scale ranging from 0 (no symptoms) to 6 (death). Lower scores indicate better functional outcome.

  3. MMA identification rate

    Time frame: Intra-operative

    Deviation between Planned and Actual Burr-hole Sites: MMA identification rate will be reported as a percentage.

  4. Number of participants experiencing one or more peri-operative surgical or medical complications

    Time frame: Intra-operative through 30 days post-operatively

    Incidence of Peri-Operative Complications:Number of participants experiencing one or more peri-operative surgical or medical complications (e.g., wound infection, seizure, pneumonia, venous thromboembolism, acute subdural haematoma). Reported as a count and percentage.

  5. Length of Hospital Stay

    Time frame: up to 30 days

    Length of Hospital Stay: Length of hospital stay is defined as the number of days from admission to discharge.

  6. All-cause Mortality

    Time frame: Within 3 months after surgery

    All-cause Mortality: Proportion of participants who die from any cause during follow-up; reported as percentage.

Study contacts

Contact information is provided by the study sponsor or research team.

Jie Shen, MD

CONTACT

[email protected]

+8613515515154

Sponsors and collaborators

Lead sponsor

The Second Hospital of Anhui Medical University

Other

Collaborators

  • Xijing Hospital

Registry information

Official study title

Three-Dimensional Printed Template-Guided Burr-Hole Drainage Combined With Intraoperative Middle Meningeal Artery Coagulation for Preventing Recurrence of Chronic Subdural Hematoma: A Multicenter Randomized Controlled Trial

Acronym: 3D-MMA-cSDH Tr

Important dates

Study start
2027
Primary completion
2028
Study completion
2029
First posted
Jul 22, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.